Skip to main content
. 2023 Jan 5;33(1):1–7. doi: 10.2188/jea.JE20200618

Table 1. Basic characteristics according to the self-reported treatment history for H. pylori among ever-infected subjects in the JPHC-NEXT Study.

  Overall Untreateda Years from treatmenta

<1Y 1–5Y 6Y+
Total, n (%) 28,696 (100.0) 22,420 (78.1) 1,100 (3.8) 2,889 (10.1) 2,287 (8.0)
Age, years, mean (SD) 61.7 (8.4) 61.7 (8.5) 61.7 (8.3) 61.6 (8.1) 61.5 (7.8)
Sex          
 Male, n (%) 12,857 (100.0) 9,583 (74.5) 484 (3.8) 1,429 (11.1) 1,361 (10.6)
 Female, n (%) 15,839 (100.0) 12,837 (81.0) 616 (3.9) 1,460 (9.2) 926 (5.8)
Serum pepsinogen          
 PG I, IQR, ng/mL 60.2 (36.5–74.6) 61.4 (36.8–77.4) 43.0 (31.2–58.8) 45.7 (34.4–60.7) 52.3 (41.0–69.7)
 PG II, IQR, ng/mL 19.4 (9.9–25.4) 21.7 (12.7–27.8) 8.2 (6.4–11.3) 8.5 (6.7–11.5) 9.8 (7.6–13.0)
 PG I/II ratio, mean (SD) 3.6 (2.0) 3.1 (1.7) 5.1 (1.9) 5.4 (1.8) 5.5 (1.7)
Serum AGb, n (%)c 10,001 (34.9) 9,565 (42.7) 133 (12.1) 181 (6.3) 122 (5.3)

AG, atrophic gastritis; IQR, interquartile range; n, number; PG, pepsinogen; SD, standard deviation.

aSubjects were classified according to their self-reported treatment history for H. pylori as follows: none: untreated; treated less than 1 year: <1Y; treated 1 to 5 years ago: 1–5Y; and treated 6 or more years ago: 6Y+.

bDefined as a combination of the serum PG I level ≤70 ng/mL and PG I/II ratio ≤3.0.

cPercentage of atrophic gastritis by pepsinogen.